Skip to main navigation Skip to search Skip to main content

What's new on giant cell tumor of bone

  • Shinji Tsukamoto
  • , Costantino Errani
  • , Tessa Balach
  • , Tomas Zamora
  • , Eduardo Ortiz-Cruz
  • , Raja Bhaskara Rajasekaran
  • , Raymond Yau
  • , Tao Ji
  • , Israel Pérez-Muñoz
  • , Francisco Linares
  • , Andrea Angelini
  • , Pietro Ruggieri
  • , Joseph Benevenia
  • , Andreas F. Mavrogenis
  • Nara Medical University
  • IRCCS Istituto Ortopedico Rizzoli - Bologna
  • The University of Chicago
  • Pontificia Universidad Católica de Chile
  • Hospital Universitario La Paz
  • Ganga Medical center &Hospital
  • The University of Hong Kong
  • Peking University
  • Hospital Ramon y Cajal
  • University of Padua
  • UMDNJ -New Jersey Medical School
  • National and Kapodistrian University of Athens

Research output: Contribution to journalReview articlepeer-review

Abstract

When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.

Original languageEnglish
Article number2
JournalSICOT-J
Volume12
DOIs
StatePublished - 2026

Keywords

  • Curettage
  • Denosumab
  • Giant cell tumor of bone
  • RFA
  • Recurrence
  • TRACP 5b

Fingerprint

Dive into the research topics of 'What's new on giant cell tumor of bone'. Together they form a unique fingerprint.

Cite this